23:07 , Aug 15, 2019 |  BC Innovations  |  Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

Adaptive’s float to more than $5 billion after its June IPO is largely based on its ambition to compete with the likes of Grail and Guardant in early diagnosis of cancer and other diseases by...
00:48 , Jul 26, 2019 |  BC Innovations  |  Product Development

Institute for Protein Design's de novo revolution

Seattle's Institute for Protein Design is growing an army of spinouts that build proteins from the ground up. With applications ranging from multivalent vaccines and synthetic cytokines to precision cell therapies, these companies could put...
06:27 , Feb 27, 2019 |  BioCentury  |  Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
22:54 , Nov 17, 2017 |  BioCentury  |  Finance

Stepwise progress

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with...
05:08 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round...
00:11 , Nov 15, 2017 |  BC Extra  |  Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
00:30 , Oct 12, 2017 |  BC Innovations  |  Product R&D

Artificial mini proteins

Virvio Inc. has spun out of a group from the University of Washington to develop artificial mini proteins as novel influenza therapeutics. The mini proteins, typically ranging between 30 and 50 amino acids in length,...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Nexvax2: Ph Ib data

A double-blind, placebo-controlled, Australian and New Zealand Phase Ib trial in 38 celiac disease patients on a gluten-free diet showed that twice-weekly intradermal Nexvax2 for up to 60 days was well tolerated and led to...